The DIDO1 Knockout HAP1 Polyclonal Cells product comprises a heterogeneous population of HAP1 cells engineered via CRISPR/Cas9-mediated gene disruption to ablate functional DIDO1 expression. This polyclonal knockout pool serves as a loss-of-function model for investigating the biological roles of DIDO1 without the confounding effects of clonal selection.
HAP1 is a near-haploid human cell line originally derived from the chronic myeloid leukemia cell line KBM-7, exhibiting fibroblast-like adherent morphology. The near-haploid karyotype reduces genetic redundancy, enabling unambiguous genotype?Cphenotype correlations in functional genomics studies, and is particularly well-suited for apoptosis and cancer research.
DIDO1 (Death Inducer-Obliterator 1) encodes a protein implicated in the regulation of apoptosis, transcriptional control, and genomic stability. Mechanistically, DIDO1 facilitates mitochondrial outer membrane permeabilization and subsequent caspase activation. It is activated downstream of DNA damage and p53 signaling, and acts upstream of key effectors including cytochrome c release and caspase-9/caspase-3 cascades. DIDO1 directly interacts with CASP8, CASP9, the anti-apoptotic protein BCL2L1, and the pro-apoptotic BAX, integrating signals from the intrinsic and extrinsic apoptotic pathways. Additionally, DIDO1 associates with the TFIID complex, suggesting a role in transcriptional regulation that may impact cell fate decision and stem cell pluripotency.
In the HAP1 near-haploid background, disruption of DIDO1 uncovers its essential functions in apoptotic signaling, as the absence of a second allele prevents compensation. This model is especially valuable for studying leukemia biology, given the cell line??s myeloid leukemia origin. Loss of DIDO1 may alter sensitivity to chemotherapeutic agents that induce apoptosis via p53 or death receptor pathways, providing a platform for drug resistance screening and synthetic lethality studies.
Researchers can employ this polyclonal knockout pool in a variety of assays, including western blotting and RT-qPCR to confirm DIDO1 ablation, apoptosis assays and cell viability analyses to assess apoptotic responses, and flow cytometry for caspase activation markers. The cells are suitable for RNA-seq transcriptomic profiling to explore DIDO1-dependent gene expression programs and co-immunoprecipitation studies to interrogate protein interaction networks. Furthermore, they serve as a robust model for leukemia research and stem cell differentiation studies where apoptosis and genomic integrity are critical. For technical specifications and ordering, please contact Ascent Research.
